Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Azd8205 – Application in Therapy and Current Clinical Research
First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 ...
Novel ADC AZD8205 demonstrates manageable safety profile and ...
ESMO 2024: Novel ADC AZD8205 demonstrates manageable safety profile and ...
AstraZeneca's AZD8205 Clinical Trial Application Approved
AZD8205 for Endometrial Cancer Clinical Trial 2025 | Power
ESMO：新型 ADC AZD8205 在首次人体试验中表现出可控的安全性和初步疗效 - M.D.安德森癌症中心
ESMO: Novel ADC AZD8205 demonstrates manageable safety profile and ...
AZD8205 for Endometrial Cancer Clinical Trial 2024 | Power
Azd8205 – Aplicación en terapia e investigaciones clínicas actuales
AZD8205 Phase I/IIa Trial Result | ESMO 2024
AZD8205 Phase I/IIa Trial Result | ESMO 2024 | DelveInsight Business ...
Emerging ADC Targets: B7-H3 and B7-H4
阿斯利康AZD批准8205临床试验申请-试药员招聘与临床试验信息平台
Extensive Biotransformation Profiling of AZD8205, an Anti-B7-H4 ...
AZD8205（B7-H4 ADC）联合AZD5305的临床前研究 - 平头哥
阿斯利康 B7-H4 ADC 国内临床即将启动！中国研发提速中_药物_Enhertu_研究
Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody ...
阿斯利康：自研 B7-H4 ADC 国内启动临床_Insight_药物_包括
B7-H4 ADC AZD8205，首次披露临床结果_Insight_患者_治疗
Abstract 1765: Discovery and first disclosure of AZD8205, a B7-H4 ...
Abstract 2947: Preclinical evaluation of a novel B7-H4 targeted ...
606O Initial results from a first-in-human study of the B7-H4-directed ...
靶向B7-H4，新型ADC药物AZD8205 在HR+/HER2–晚期乳腺癌临床研究中显疗效 - MedFind
Puxitatug (INT-016) | Anti-VTCN1/B7-H4 Antibody | MedChemExpress
puxitatug samrotecan (AZD8205) / AstraZeneca
B7-H4 Offers Potential Treatment Target in a Variety of Solid Tumors
AZD-8205(AZD-8205) - 药物靶点：B7-H4 x Top I_在研适应症：恶性实体肿瘤，转移性子宫内膜恶性肿瘤，腺样囊性癌 ...
Immunological mechanisms and antibody-drug conjugates targeting B7-H3 ...
AZD-8205(AZD-8205) - 药物靶点：B7-H4 x Top I_在研适应症：子宫内膜癌，恶性实体肿瘤，转移性子宫内膜恶性肿瘤 ...
2024年ESMO：抗体偶联药AZD8205 的首次人体临床试验数据公布，多个肿瘤类型迎来新希望！医药新闻-ByDrug-一站式医药资源共享 ...
B7家族的泛癌种新星：B7-H4 - 知乎
B7H4 ADC + PARPi + PD-1/TIGIT 双抗，三联疗法国内获批临床_Insight_开发_治疗
Mersana靶向B7-H4 ADC获FDA快速通道认定医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
B7-H4: A potential therapeutic target in adenoid cystic carcinoma - PMC
阿斯利康 B7H4 ADC 新药国内启动 III 期临床|阿斯利康_新浪财经_新浪网
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 ...
肿瘤免疫 | 广谱抗癌靶点：B7-H3/B7-H4医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
阿斯利康B7H4 ADC新药在中国启动III期临床试验
有效载荷（payload）的多样性：ADC药物未来开发的关键一环 - 脉脉
2024年ESMO：抗体偶联药AZD8205 的首次人体临床试验数据公布，多个肿瘤类型迎来新希望！_腾讯新闻
【AACR 2023】ADC药物”角力”AACR-公司新闻-北京百普赛斯生物科技股份有限公司
AZD8205-hIgG1 - Kyinno Bio
B7-H4 | B7家族又一肿瘤治疗潜力靶点
Puxitatug (INT-016) | 抗VTCN1/B7-H4抗体 | MCE
阿斯利康三联疗法获国内临床批准：B7H4 ADC联合PARP及PD-1-TIGIT 双抗
Puxitatug samrotecan drug-linker (AZD8205 drug-linker) | Drug-Linker ...
Safety and preliminary efficacy of puxitatug samrotecan (AZD8205) in ...
2024年ESMO：抗体偶联药AZD8205 的首次人体临床试验数据公布，多个肿瘤类型迎来新希望！-MedSci.cn
中美合作！抗癌新藥AZD8205有效治療癌症得到證實！ - 每日頭條
子宫内膜癌新药临床试验：ADC药物Puxitatug Samrotecan（AZD8205）-印塔健康官网
阿斯利康自研ADC崛起_腾讯新闻
B7家族的多面光辉 - 知乎
What Are Antibody-Drug Conjugates or ADCs? | ADC Review ADC Review
WO2024223899A1 - B7-h4 therapeutic binding molecules for the treatment ...
高达32亿美元！B7-H3和B7-H4的ADC还有哪些选手？医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
两个月达成超32亿合作！GSK斥资翰森背后的靶向B7-H3/B7-H4 ADC究竟有何魅力？
Analytical Chemistry Vol. 96 No. 42 - ACS Publications
【重磅】晚期子宮內膜癌治療新突破！AZD8205 ADC療法疾病控制率超80% - 藥時事 Drugnews (@drugnews) | Dcard
300MO Puxitatug samrotecan (P-Sam, AZD8205) in patients (pts) with HR+ ...
抗体药物偶联物(ADC)和泛偶联物(XDC)在卵巢癌中的临床证据汇总(2025.6) - 知乎
阿斯利康自研ADC崛起_患者_Elahere_药物
Antibody-Drug Conjugates: Functional Principles and Applications in ...
Antibody-drug Conjugate Information | ADCdb
Antibody Drug Conjugate Structure
